Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sutro Biopharma, Inc. (STRO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.56-0.68 (-4.19%)
At close: 04:00PM EST
15.56 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close16.24
Open16.24
Bid15.00 x 1200
Ask19.59 x 1100
Day's Range15.43 - 16.24
52 Week Range15.00 - 28.30
Volume270,892
Avg. Volume226,760
Market Cap719.966M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-2.85
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for STRO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sutro Biopharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    Sutro Biopharma to Participate in Two Upcoming Investor Conferences

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in two upcoming virtual investor conferences.

  • PR Newswire

    Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Heidi Hunter has been appointed to Sutro's Board of Directors.

  • Zacks

    Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

    Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 0.00% and -3.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement